COWA LLC’s Viking Therapeutics VKTX Stock Holding History

COWA LLC’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,530	Closed	-$245K	–	184
2026 Q1	$245K	Sell	7,530 -139	-2%	-$4.47K	0.07%	140
2025 Q4	$270K	Buy	+7,669	New	+$272K	0.08%	133

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

COWA LLC's VKTX Position: Q2 2026 in Review

COWA LLC sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 7,530 shares — an estimated $245K sold.

COWA LLC first reported a position in VKTX in Q4 2025 and held it in 2 quarters. The position peaked at $270K in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

COWA LLC reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
COWA LLC sold 7,530 Viking Therapeutics shares in Q2 2026, an estimated $245K.
COWA LLC first reported a position in Viking Therapeutics in Q4 2025 and held it in 2 quarters.
COWA LLC's Viking Therapeutics position peaked at $270K in Q4 2025.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on COWA LLC's 13F filing for Q2 2026, filed 6 Aug 2026.